Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lev Pharmaceuticals has entered into multi-year agreements with CuraScript, CVS Caremark and FFF Enterprises to serve as its specialty pharmacy, specialty distribution and patient services partners to support the US commercialization of Cinryze, an investigational treatment for hereditary angioedema, also known as C1 inhibitor deficiency.
Subscribe to our email newsletter
Lev has also announced plans to launch LevCare, a program designed to ensure that patients have ready access to Cinryze once it becomes commercially available in the US.
CuraScript and CVS Caremark will provide specialty pharmacy and specialty distribution services that deliver Cinryze directly to patients, clinics and physicians. FFF Enterprises will serve as Lev’s third party logistics provider and specialty distributor to supply Cinryze to hospitals, clinics and physicians.
LevCare, which will be administered by TheraCom, a division of CVS Caremark, will provide support services to patients and physicians, such as benefit coverage investigations, prior authorizations, case management and broad-based reimbursement assistance.
Judson Cooper, chairman of Lev, said: “By employing a ‘limited distribution model’ through the comprehensive, co-ordinated and integrated services of CuraScript, CVS Caremark, FFF Enterprises and LevCare, we will be well positioned to provide patients with broad access to Cinryze pending FDA approval.”